Prognostic value of SUV<sub>max</sub>for locally advanced non-small cell lung cancer patients treated with synchronous cetuximab plus concurrent chemoradiotherapy

刘笛; 陈佳艳; 沈钰新; 赵伟新; 傅小龙; 蒋国樑; 樊旼

doi:10.3969/j.issn.1007-3969.2014.03.012

您当前的位置：

首页 >

文章列表页 >

Prognostic value of SUV_maxfor locally advanced non-small cell lung cancer patients treated with synchronous cetuximab plus concurrent chemoradiotherapy

更新时间：2025-12-31

- Prognostic value of SUV_maxfor locally advanced non-small cell lung cancer patients treated with synchronous cetuximab plus concurrent chemoradiotherapy
- China Oncology Vol. 24, Issue 3, Pages: 225-230(2014)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院放疗科，复旦大学上海医学院肿瘤学系,上海,200032
  2. 南京医科大学附属南京第一医院放疗科,江苏,南京,210006
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.03.012
  CLC：
- Published Online：01 April 2014，
  
  Published：01 April 2014
- 稿件说明：
移动端阅览
刘笛,陈佳艳,沈钰新,赵伟新,傅小龙,蒋国樑,樊旼. PET/CT标准摄取值与Ⅲ期非小细胞肺癌西妥昔单抗联合同期放化疗预后相关性的研究[J]. 中国癌症杂志, 2014, 24(3): 225-230.

刘笛, 陈佳艳, 沈钰新, et al. Prognostic value of SUV_maxfor locally advanced non-small cell lung cancer patients treated with synchronous cetuximab plus concurrent chemoradiotherapy[J]. China Oncology, 2014, 24(3): 225-230.
刘笛,陈佳艳,沈钰新,赵伟新,傅小龙,蒋国樑,樊旼. PET/CT标准摄取值与Ⅲ期非小细胞肺癌西妥昔单抗联合同期放化疗预后相关性的研究[J]. 中国癌症杂志, 2014, 24(3): 225-230. DOI： 10.3969/j.issn.1007-3969.2014.03.012.

刘笛, 陈佳艳, 沈钰新, et al. Prognostic value of SUV_maxfor locally advanced non-small cell lung cancer patients treated with synchronous cetuximab plus concurrent chemoradiotherapy[J]. China Oncology, 2014, 24(3): 225-230. DOI： 10.3969/j.issn.1007-3969.2014.03.012.

摘要

背景与目的：PET/CT在非小细胞肺癌(non-small cell lung cancer，NSCLC)的预后判断中有重要价值，但单独针对Ⅲ期且接受靶向治疗患者的研究较少。本研究旨在探讨在这些患者中

F氟代脱氧葡萄糖(

F-fluorodeoxyghcose，

F-FDG)PET/CT基线标准摄取值(standard uptake value，SUV)与预后的相关性。方法：前瞻性分析复旦大学附属肿瘤医院放疗科2009年9月—2012年7月入组的17例接受西妥昔单抗(cetuximab，C225)联合顺铂+长春瑞宾(NP方案)诱导化疗及同期放化疗的患者，入组前两周内完成PET/CT检查。采用Cox回归风险比例模型对SUV-T、SUV-N、SUV-TOTAL、性别、年龄、组织学类型、TNM分期、功能状态评分(performance status，PS)、吸烟状态与患者生存时间进行单因素生存分析，差异有统计学意义者进行多因素生存分析。Log-rank检验及Kaplan-Meier法分别评估以SUV-T、SUV-N、SUV-TOTAL界值分组患者间生存期的差异并绘制生存曲线。结果：单因素预后分析提示，上述SUV

max

、PS评分、吸烟状态与预后相关，其中SUV-T及SUV-N的界值是11、SUV-TOTAL为20。多因素分析结果显示，SUV-TOTAL(P=0.012)、SUV-T(P=0.025)、SUVN(P=0.033)是影响本组患者生存的独立预后因素，其中SUV-TOTAL20组患者的相对危险度(hazard ratio，HR)为14.7。结论：对于C225联合同步放化疗的患者，PET/CT局部区域、原发灶及纵隔淋巴结SUV值与预后有一定相关性，值得进一步大样本研究。将3者结合起来，可指导该治疗的合理应用。

Abstract

Background and purpose: We investigated whether fluorine-18 fluorodeoxyglucose (

F-FDG) maximal standard uptake value (SUV

max

) of the primary tumor (SUV-T)

SUV

max

of the regional lymph nodes (SUV-N) or the overall loco-regional lesion SUV

max

(SUV-TOTAL) was related to survi

val of patients with stage Ⅲ nonsmall cell lung cancer (NSCLC) who received Cetuximab and combined definitive chemoradiotherpay. Methods: From September 2009 to July 2012

seventeen patients with unresectable stage Ⅲ NSCLC receiving cetuximab with cisplatin/vinorelbine (NP) followed by concomitant NP and intensity-modulated radiotherapy (IMRT) at the Fudan University Shanghai Cancer Center were enrolled onto a prospectively study. All patients received positron emission tomography/computerized tomography (PET/CT) scans within 2 weeks before enrolment. Univariate analysis were used to assess the correlation between SUV-T

SUV-N

SUV-TOTAL

gender

age

histology

tumour-node-metastasis (TNM) stage

performance status (PS) as well as smoking status and survival. The factors which showed statistical significance entered into multivariate Cox-regression model. Survival functions of different populations were estimated by Kaplan-Meier method and compared by Log-rank test. Results: In the univariate analysis

SUV-T

SUV-N

SUVTOTAL

PS and smoking status were prognostic factors. The best cut-off values for SUV-T

SUV-N and SUV-TOTAL were 11

11 and 20

respectively. Multivariate analysis revealed that SUV-TOTAL (P=0.012)

SUV-T (P=0.025)

and SUV-N (P=0.033) were independent predictors of survival with hazard ratio (HR) of 14.7

11.2

and 6.2

respectively. Conclusion: Local

regional and locoregional maximal SUVs defined by 18F-FDG PET-CT scanning may have a strong correlation with survival in this patients setting

which merits further study.

关键词

Keywords

references

Views

3865

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A cohort study of prognostic value of ¹⁸F-FDG PET/CT metabolic parameters in patients with diffuse large B-cell lymphoma treated with CAR-T

Value of pretreatment ¹⁸F-FLT PET/CT and ¹⁸F-FDG PET/CT uptake heterogeneity for early prediction of treatment outcome in locally advanced nasopharyngeal carcinoma

Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer

Clinical research progress of tumor mutational burden inEGFR-mutant advanced non-small cell lung cancer

The analysis of treatment decision and prognosis of stage Ⅲ non-small cell lung cancer in the multidisciplinary team

Related Author

Chao HE

Yeye ZHOU

Bin ZHANG

Shengming DENG

Guang MA

Xiaomin OU

Chaosu HU

Shaoli SONG

Related Institution

Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Center for Biomedical Imaging, Fudan University; Shanghai Engineering Research Center for Molecular Imaging Probes

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

上海交通大学附属胸科医院放疗科

上海交通大学医学院

AI问答

⁰

Prognostic value of SUVmaxfor locally advanced non-small cell lung cancer patients treated with synchronous cetuximab plus concurrent chemoradiotherapy

DOI：10.3969/j.issn.1007-3969.2014.03.012

摘要

Abstract

关键词

Keywords

references

Prognostic value of SUV_maxfor locally advanced non-small cell lung cancer patients treated with synchronous cetuximab plus concurrent chemoradiotherapy